A Comprehensive Comparative Effectiveness and Safety Study of the Second Antihypertensive Agent after Monotherapy at scale using the OHDSI AP Network

Yuan Lu1,2, Jing Li1,2, Sang Youl Rhee1,4, Hua Xu1,5, Nicole Pratt1,4, Seng Chan You1,7, Mui Van Zandt1,3, Mengling Feng1,16, Lei Liu1,9, Ian Chi Kei Wong1,10, Rae Woong Park1,2, Jiyoung Hwang1,3, Tatsuo Hiramatsu1,13, Usman Iqbal1,12, Yu-Chuan Li1,13, Min-Huei Hsu1,13, Jitendra Jonnagaddala14, Christian Reich1,3

1 Observational Health Data Sciences and Informatics, New York, USA; 2 Center for Outcomes Research & Evaluation (CORE), Yale University, New Haven, CT, USA; 3 Real World Solutions, IQVIA, Durham, NC, USA; 4Kyung Hee University Medical Center, Seoul, Korea; 5School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA; 6Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, South Australia, Australia; 7Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea; 8Saw Swee Hock School of Public Health, National University Health System, National University of Singapore, Singapore; 9Shanghai Medical College of Fudan University, Shanghai, China; 10Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong Special Administrative Region, China; 11Innovation & Research Support Center, International University of Health and Welfare (IUHW), Tokyo, Japan; 12College of Public Health, Taipei Medical University, Taipei City, Taiwan; 13Research Center for Artificial Intelligence in Medicine, Taipei Medical University, Taipei City, Taiwan; 14University of New South Wales, Australia.

Background

Hypertension is a leading cause of death and disability across the world1. Although many antihypertensive agents are available to treat hypertension, there remains considerable uncertainty regarding the optimal choice of a second agent to add onto monotherapy for hypertension, which is necessary for a substantial proportion of patients. Clinical trials have not provided head-to-head comparisons of the effectiveness and safety associated with the second line antihypertensive agents after monotherapy to control blood pressure14. The lack of high-quality evidence addressing this question means that guidelines are unable to provide recommendations about the preferred choice of medication for treatment escalation9,10. A better understanding of the comparative effectiveness and safety of different classes of second antihypertensive agents added to monotherapy, with attention to relevant subgroups of patients defined by demographic, geographic and clinical factors, has a great potential to inform clinical decisions.

Methods

This study is an extension of the Large-Scale Evidence Generation and Evaluation across a Network of Databases for Hypertension (LEGEND-HTN) initiative. We pursued three aims: (1) to describe real-world treatment variation in common antihypertensive agents added to monotherapy among patients with hypertension by demographic, clinical, and geographic subgroups; (2) to determine real-world effectiveness of common antihypertensive agents added to monotherapy for three primary (acute myocardial infarction, heart failure, and stroke) and six secondary effectiveness outcomes; and (3) to determine real-world risks of adverse events and benefits on 46 safety outcomes.

We developed and implemented a systematic, large-scale observational study that provided comprehensive pairwise comparisons between dual combinations of any of the four major antihypertensive agent classes to answer questions in Aims 1-3. In contrast to a single comparison approach, this study provided a comprehensive view of the findings and their consistency across populations, drugs, and outcomes. We modelled the study on the LEGEND-HTN collaborative research evaluating the comparative effectiveness of first-line antihypertensive monotherapies recently published in The Lancet2. The study followed a workflow described in Figure 1.

Results

We have designed 12 cohorts based on the different combinations of the four main antihypertensive agents as the first-step feasibility study. Below are the results from the committed APAC data sources.

Conclusions

This is the first collaborative effort of the newly established OHDSI Asia Pacific group. Although the project is still undergoing, the initial analyses support the feasibility of the study and show significant variations in treatment utilization across countries. Following the LEGEND principles of open, reproducible and reliable science, this work will bridge important knowledge gaps in treatment escalation for hypertension. The contribution will be significant as it provides critical information to inform treatment decisions facing patients with hypertension, their caregivers, clinicians, policymakers and healthcare system leaders in Asia Pacific region.

Reference